Cognition Therapeutics (CGTX) announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies, DLB. The Company anticipates that topline results will be available in December 2024. Lisa Ricciardi, Cognition’s president and CEO, concluded, “We look forward to reviewing the results of this study to enhance our understanding of CT1812’s tolerability profile and identify signals of efficacy across measures of cognition and function.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue